Indium Oxine

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

Indium(111In) hydroxyquinoline

Available from:

GE Healthcare Australia Pty Ltd

Class:

Medicine Registered

Patient Information leaflet

1-020605

INDIUM [111IN] OXINE SOLUTION 

_ _

CONSUMER MEDICINE INFORMATION 

WHAT IS IN THIS LEAFLET? 

This leaflet answers some common 
questions about
 Indium [
111
In] Oxine 
solution..  It does not contain all the 
available information, nor does it take 
the place of talking to your doctor or  
treatment provider. 

All medicines have risks and benefits.  
Your doctor has weighed the risks of 
you being treated with Indium [
111
In] 
Oxine solution 
against the expected benefits. 

IF YOU HAVE ANY CONCERNS ABOUT 
BEING GIVEN THIS PREPARATION, ASK 
YOUR DOCTOR OR TREATMENT PROVIDER. 

KEEP THIS LEAFLET.   You may need to 
read it again. 

WHAT INDIUM [111IN] 
OXINE SOLUTION IS USED 
FOR 

Indium [
111
In] Oxine solution is a 
radiopharmaceutical which is a 
medicinal product containing a small 
amount of radioactivity. Such 
radiopharmaceuticals are given in 
small amounts to find out or rule out a 
disease. A sample of your blood will 
be taken and mixed with the product to 
label some of the blood cells with 
radioactivity. This blood sample will 
be re-injected into your body to help to 
find infections such as abcesses in your 
abdomen, infections inside your bones 
and other types of infections and 
conditions. The radiation that your 
body receives is very low and is 
considered safe. The labelled blood 
cells circulate in the body and may 
temporarily collect in a particular area 
of tissue. The radioactivity can be 
detected from outside the body using 
special cameras, and a picture, known 
as a scan, can be taken. This scan will 
show the distribution of the 
radioactivity within your body. This 
can give the doctor valuable 
information about the location of 
inflammation or possible tissue damage 
or disease 

Your doctor will explain for which 
particular purpose he/she is using 
Indium [
111
In] Oxine solution. 

Indium [
111
In] 

Summary of Product characteristics

11. W
ithdraw half the volume (~2.5 mL) of the platelet
-poor plasma pr
epar
ed in step 4 into a 
20 mL syringe. W
ithdraw the labelled cell suspension into the same syringe, leaving a
r
esidual
volume of 0.2 - 0.5 mL in the tube. (This r
esidue will contain any clumps of leucocytes which have
settled during incubation and should be discar
ded.) Remove the syringe needle and transfer the
syringe contents to another 15 mL conical tube.
12.
Centrif
uge the capped tube at 80 - 90g for 7 minutes. Decant the supernatant
and r
esuspend the
cell pellet in 10 mL saline as described in step 6.
13.
W
ithdraw the r
emaining volume of platelet
-poor plasma (step 4) into a fr
esh 20 mL syringe and
withdraw the 
111
In-labelled cell suspension into the same syringe. Measur
e the total activity
pr
esent and if necessary discar
d any excess volume to leave the r
equir
ed patient dose.
14.
Administer the 
111
In -labelled leucocyte suspension by slow intravenous injection using
a 19G
needle.
PR
OCEDURE FOR THE PREP
ARA
TION AND ADMINISTRA
TION OF INDIUM-111 L
A
BELLED PL
AT
ELE
TS
Aseptic technique should be used thr
oughout
.
Good pharmaceutical practice for the pr
eparation of sterile solutions should be followed. All sterile
solutions should be fr
eshly pr
epar
ed. Analytical grade chemicals should be used thr
oughout
.
This pr
ocedur
e for the Indium-111 labelling of the patient’s own platelets is
described by Hawker et
al. HA
WKER RJ
, HA
WKER LM and WILKINSON AR
. Indium [
111
In] labelled human platelets: optimal
method. Clinical Science. V
ol 58, pp243-248,
1980. The pr
ocedur
e takes appr
oximately 1 hour and
aseptic technique must be used thr
oughout
.
PLAT
ELET HANDLING
The following general points should be noted in connection with the pr
ocedur
e.
(1)
Turbulence and fr
othing during pipetting stages should be par
ticularly avoided, especially when
the platelet pellet is r
esuspended.
(2)
Damage to platelets may r
esult fr
om sudden temperatur
e changes.
(3) 
Tubes should be kept stopper
ed whenever possible t